Background Anti-vascular endothelial growth factor (VEGF) therapy shows promise in the
Background Anti-vascular endothelial growth factor (VEGF) therapy shows promise in the treating high-grade gliomas (HGG). 21/28 time regimen. Outcomes Fifty-nine sufferers had been enrolled, 21 in arm 1, 20 in arm 2 and 18 in arm 3. Median age group was 56 years (24-69); median KPS 90 (60-100). The utmost tolerated dosage (MTD) of aflibercept … [Read more…]